Literature DB >> 18243839

Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy.

Jae Min Jeong1, F F Russ Knapp.   

Abstract

This work describes the installation, use, and quality control (QC) of the alumina-based tungsten-188 ((188)W)/rhenium-188 ((188)Re) generators provided by the Oak Ridge National Laboratory (ORNL). In addition, methods used for concentration of the (188)Re-perrhenate bolus and preparation of (188)Re-labeled HDD (4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) for trans-arterial administration for therapy of nonresectable liver cancer also are described. The (188)W/(188)Re generator has a long useful shelf-life of several months and is a convenient on-site (188)Re production system. (188)Re has excellent therapeutic and imaging properties (T(1/2) 16.9 hours; E(betamax) 2.12 MeV; 155-keV gamma ray, 15%) and is cost effectively obtained on demand by saline elution of the generator. The clinical efficacy of a variety of (188)Re-labeled agents has been demonstrated for several therapeutic applications. Because of the favorable physical properties of (188)Re, several (188)Re-labeled agents are being developed and evaluated for the treatment of nonresectable/refractory liver cancer. (188)Re-labeled HDD has been the most widely studied of these agents for this application and has been introduced into clinical trials at a number of institutions. The trans-arterial administration of (188)Re-labeled agents for treatment of inoperable liver cancer requires use of high-level (1-2 Ci) (188)W/(188)Re generators. The handling of such high levels of (188)Re imposes radiological precautions normally not encountered in a radiopharmacy and adequate care and ALARA (ie, "As Low As Reasonably Achievable") principles must be followed. The ORNL generator provides consistently high (188)Re yields (>75%) and low (188)W parent breakthrough (<10(-3)%) over an extended shelf-life of several months. However, the high elution volumes (20-40 mL for 1-2 Ci generators) can require concentration of the (188)Re bolus by postelution passage through silver cation chloride trapping columns used in the cost-effective tandem cation/anion column system. The silver column removes the high levels of chloride anion as insoluble AgCl, thus allowing subsequent specific trapping of the perrhenate anion on the small (QMA SeaPak) anion column. This method permits subsequent elution of (188)Re-perrhenate with a small volume of saline, providing a very high activity-concentration solution. Because the (188)Re-specific volume-activity concentration continually decreases with time, the tandem system is especially effective method for extending the useful generator shelf-life. Low elution flow rates (<1 mL/min) minimize any high back pressure which may be encountered during generator/tandem column elution when using tightly packed, small-particle-size commercial columns. In-house preparation of silver cation columns is recommended since the chloride trapping capacity is essentially unlimited, it is inexpensive and not limited in availability to any one supplier, and back pressure can be eliminated by the use of larger particles. Methods for the preparation of (188)Re-HDD have been optimized and this agent can be obtained in high yield (80%).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243839     DOI: 10.1053/j.semnuclmed.2007.10.003

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  5 in total

1.  The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts.

Authors:  Carol A Nelson; Michael T Azure; Christopher T Adams; Kurt R Zinn
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

Review 2.  KSNM60: The History of Radiopharmaceutical Sciences in Korea.

Authors:  Ran Ji Yoo; Yun-Sang Lee; Kyo Chul Lee; Dong Wook Kim; Dong-Yeon Kim; Yearn Seong Choe; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2022-04-05

3.  Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy.

Authors:  Maria Argyrou; Alexia Valassi; Maria Andreou; Maria Lyra
Journal:  Int J Mol Imaging       Date:  2013-04-09

4.  Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo.

Authors:  Xidong Wu; Huiyu Liang; Yan Tan; Chao Yuan; Shuji Li; Xiaowen Li; Guiping Li; Yusheng Shi; Xingmei Zhang
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

Review 5.  Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy.

Authors:  Hui Shan Liew; Chun-Wai Mai; Mohd Zulkefeli; Thiagarajan Madheswaran; Lik Voon Kiew; Nicolas Delsuc; May Lee Low
Journal:  Molecules       Date:  2020-09-12       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.